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Albert Komba, Moses N Ndiritu, Shahnaaz K Sharif, Kevin Marsh, James A Berkley, J Anthony G Scott
Summary
Background In sub-Saharan Africa, more than 90% of children with sickle-cell anaemia die before the diagnosis can 
be made. The causes of death are poorly documented, but bacterial sepsis is probably important. We examined the 
risk of invasive bacterial diseases in children with sickle-cell anaemia.
Methods This study was undertaken in a rural area on the coast of Kenya, with a case–control approach. We undertook 
blood cultures on all children younger than 14 years who were admitted from within a deﬁ ned study area to Kiliﬁ  
District Hospital between Aug 1, 1998, and March 31, 2008; those with bacteraemia were deﬁ ned as cases. We used 
two sets of controls: children recruited by random sampling in the same area into several studies undertaken between 
Sept 1, 1998, and Nov 30, 2005; and those born consecutively within the area between May 1, 2006, and April 30, 2008. 
Cases and controls were tested for sickle-cell anaemia retrospectively.  
Findings We detected 2157 episodes of bacteraemia in 38 441 admissions (6%). 1749 of these children with bacteraemia 
(81%) were typed for sickle-cell anaemia, of whom 108 (6%) were positive as were 89 of 13 492 controls (1%). The 
organisms most commonly isolated from children with sickle-cell anaemia were Streptococcus pneumoniae (44/108 
isolates; 41%), non-typhi Salmonella species (19/108; 18%), Haemophilus inﬂ uenzae type b (13/108; 12%), Acinetobacter 
species (seven of 108; 7%), and Escherichia coli (seven of 108; 7%). The age-adjusted odds ratio for bacteraemia in 
children with sickle-cell anaemia was 26·3 (95% CI 14·5–47·6), with the strongest associations for S pneumoniae 
(33·0, 17·4–62·8), non-typhi Salmonella species (35·5, 16·4–76·8), and H inﬂ uenzae type b (28·1, 12·0–65·9).
Interpretation The organisms causing bacteraemia in African children with sickle-cell anaemia are the same as those 
in developed countries. Introduction of conjugate vaccines against S pneumoniae and H inﬂ uenzae into the childhood 
immunisation schedules of African countries could substantially aﬀ ect survival of children with sickle-cell anaemia. 
Funding Wellcome Trust, UK.
Introduction 
Bacterial infections are a major cause of morbidity and 
mortality in children with sickle-cell anaemia. Several 
organisms, including Streptococcus pneumoniae, 
Haemophilus inﬂ uenzae, and non-typhi Salmonella 
species, have been identiﬁ ed as important causative 
agents through studies undertaken in the USA.1–4 The 
introduction of penicillin prophylaxis and immunisation 
with conjugate vaccines directed against S pneumoniae 
and H inﬂ uenzae type b have led to substantial 
improvements in the prognosis of patients born with 
sickle-cell anaemia in developed countries.5,6 In Africa, 
where more than 80% of all children with this disease are 
born,7 a scarcity of data has impeded development of 
evidence-based guidelines;8–13 however, available data 
suggest that the range of organisms causing invasive 
bacterial disease in African patients with sickle-cell 
anaemia might diﬀ er from that described in the USA,8–12 
leading to calls for further studies to guide policy.12,14
A potential bias in many of the studies undertaken in 
Africa has been their focus on people with an existing 
diagnosis of sickle-cell anaemia. Because diagnosis is 
often delayed in Africa, studies conﬁ ned to known cases 
will under-report events in young children. Although 
cohort studies based on neonatal screening programmes 
could circumvent this problem,15 such programmes are 
expensive and time-consuming, and the medical 
follow-up received by aﬀ ected children would probably 
change the natural history of the disease. Instead of 
looking for bacterial infections in a cohort of patients 
with sickle-cell anaemia, we have examined the sickle-
cell anaemia status of a large group of consecutive 
patients admitted to hospital with bacteraemia from 
within a known denominator population. This approach 
allows an unbiased description of serious bacterial 
infections in children with sickle-cell anaemia, which we 
compared with that in children without sickle-cell 
anaemia. Further, we have quantiﬁ ed the risk of 
bacteraemia in children with sickle-cell anaemia, both in 
general and for speciﬁ c bacterial pathogens, by 
undertaking case–control analyses with two large 
community-based control groups drawn from the same 
denominator population. Finally, we have estimated the 
incidence of bacteraemia in children with sickle-cell 
anaemia in our study population from the number of 
bacteraemia episodes in this group, the size of the 
denominator population, and the prevalence of this 
disease in controls. 
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Methods
Study setting 
The study was undertaken at Kiliﬁ  District Hospital 
(KDH) on the Kenyan coast, which serves as a ﬁ rst-referral 
centre for 500 000 people. Common causes of admission 
to KDH have been reported previously.16 The burden of 
malaria, the most common diagnosis at the start of the 
study, decreased substantially as the study proceeded.17 
7% of children admitted have bacteraemia (on the basis of 
ﬁ ndings from a study undertaken between Aug 1, 1998, 
and July 31, 2002), and ﬁ ve organisms (S pneumoniae, 
non-typhi Salmonella species, H inﬂ uenzae, Escherichia 
coli, and Staphylococcus aureus) cause 70% of these 
infections.18 H inﬂ uenzae type b conjugate vaccine was 
introduced into the immunisation schedule in 
November, 2001, but pneumococcal conjugate vaccine 
has not yet been deployed. Coverage for three doses of 
pentavalent vaccine (for diphtheria, tetanus, pertussis, 
H inﬂ uenzae type b, and hepatitis B) was estimated at 
88% in 2004.19 The prevalence of HIV infection in routine 
antenatal screening at KDH was 5–7% during 2004–07. In 
2000, a system of epidemiological and demographic 
surveillance (Kiliﬁ  Epi-DSS) was established in a deﬁ ned 
area of 891 km² surrounding KDH, with a population of 
about 100 000 children younger than 14 years living in ﬁ ve 
administrative divisions.20 About 80% of children who are 
admitted to KDH live in the Kiliﬁ  Epi-DSS area. Medical 
services for children with sickle-cell anaemia are scarce in 
Kiliﬁ  district; the only specialist clinic is at KDH.
Cases and controls 
Since Aug 1, 1998, all children admitted to KDH have 
been investigated with blood cultures, apart from those 
admitted for elective procedures or for observation after 
minor accidents.18 Routine clinical and laboratory data 
have also been recorded systematically at admission. This 
study included all patients with bacteraemia aged younger 
than 14 years admitted between Aug 1, 1998, and 
March 31, 2008, who lived within the Kiliﬁ  Epi-DSS area. 
For the purpose of our case–control analyses, we deﬁ ned 
these patients as cases. The diagnosis of sickle-cell 
anaemia was based on the ﬁ nding of a major haemoglobin 
band in the position of HbS—for venepuncture samples 
on alkaline electro phoresis on cellulose acetate membrane 
(control group 1) or for capillary samples on HPLC 
(Variant Analyzer, BioRad, Hercules, CA, USA) with the 
β thalassaemia short program (control group 2). In both 
instances, HbS was conﬁ rmed by PCR.21 No patient had 
HbA (unless known to be acquired from transfusion), 
implying a diagnosis of homozygous HbS (SS) disease or 
sickle-cell β0 thalassaemia. Most patients will have had 
SS disease, but sickle-cell β0 thalassaemia has not been 
excluded; thus because of this uncertainty, we have 
chosen to use the term sickle-cell anaemia throughout 
this Article.
We used two separate sets of controls for our 
case–control analyses. Control group 1 consisted of 
children recruited by random sampling throughout the 
Kiliﬁ  Epi-DSS into several studies undertaken between 
Sept 1, 1998, and Nov 30, 2005, as described in detail 
previously;16,22–24 control group 2 included children born 
consecutively within the Kiliﬁ  Epi-DSS area between 
May 1, 2006, and April 30, 2008. Control group 2 
remains under investigation for genetic susceptibility 
to infectious diseases. Control group 1 was representative 
of cases in terms of age, sex, and ethnic group but were 
less representative of the geographic area of residence 
than was control group 2, which was highly 
representative of cases in all variables apart from age. 
Age is an important confounder because of the high 
mortality associated with sickle-cell anaemia in early 
life and the pronounced variation in bacteraemia in all 
children with age.18 We therefore did our principal 
analyses with control group 1, with adjustment for age, 
sex, and ethnic origin, and used control group 2 to 
check for any residual confounding attributable to 
variation in geographical residence.  
We obtained informed consent from the parents of all 
cases and controls. The study was approved by the the 
Kenya Medical Research Institute/National Ethical Review 
Committee.
Isolates from 
children without 
sickle-cell 
anaemia (%)
Isolates from 
children with sickle-
cell anaemia* (%)
Proportion of isolates 
in children with 
sickle-cell anaemia (%)
Gram positive
Streptococcus pneumoniae 425 (25·9%) 44 (40·7%) 10·4%
Staphylococcus aureus 173 (10·5%) 6 (5·6%) 3·5%
Group A streptococci 82 (5·0%) 0 0
Group B streptococci 35 (2·1%) 1 (0·9%) 2·9%
Other gram-positive organisms† 82 (5·0%) 4 (3·7%) 4·9%
Gram negative
Non-typhi Salmonella species 192 (11·7%) 19 (17·6%) 9·9%
Haemophilus inﬂ uenzae type b 100 (6·1%) 13 (12·0%) 13·0%
Haemophilus inﬂ uenzae other 27 (1·6%) 2 (1·9%) 7·4%
Escherichia coli 138 (8·4%) 7 (6·5%) 5·1%
Acinetobacter species 136 (8·3%) 7 (6·5%) 5·1%
Pseudomonas species 81 (4·9%) 0 0
Klebsiella species 57 (3·5%) 1 (0·9%) 1·8%
Other gram-negative organisms‡ 113 (6·9%) 4 (3·7%) 3·5%
Overall
Any organism 1641 (100·0%) 108 (100·0%) 6·6%
Data are number (%) of isolates in children without sickle-cell anaemia and in children with sickle-cell anaemia. 
The ﬁ nal column is the proportion of children with sickle-cell anaemia, which varied signiﬁ cantly by organism 
(χ²=35·4; p=0·001). *Seven of the patients with sickle-cell anaemia were admitted twice and two were admitted three 
times. In no case was the same child admitted more than once with the same organism. The total number of unique 
patients was therefore 97. †For children without sickle-cell anaemia, species included streptococci groups C (n=5), 
D (62), F (3), and G (6); and Staphylococcus saprophyticcus (3). For children with sickle-cell anaemia, species included 
group D streptococci (2) and non-typable streptococci (2). ‡For children without sickle-cell anaemia, species included 
Campylobacter species (7), Enterobacter species (26), Neisseria species (10), Proteus species (10), Salmonella typhi (8), 
and Shigella species (4). For children with sickle-cell anaemia, species included Citrobacter species (1), Enterobacter 
species (2), and S typhi species (1). 
Table 1: Bacterial isolates from patients with bacteraemia, stratiﬁ ed by sickle-cell anaemia status
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Procedures 
Blood was taken from children admitted to KDH and 
inoculated into culture bottles (BACTEC Peds Plus, 
Becton Dickinson, Franklin Lakes, NJ, USA) as described 
previously.18 A full blood count was done and an aliquot of 
blood stored at –800C for later genetic tests. Culture 
bottles were weighed before and after blood inoculation 
and processed by an automated blood-culture system 
(BACTEC 9050, Becton Dickinson). Positive samples 
were subcultured on standard media by routine 
microbiological techniques. Quality assurance was 
provided by the UK National External Quality Assessment 
Service. Clinical indications for lumbar puncture were 
impaired consciousness or meningism in children 
younger than 5 years, prostration in children younger 
than 3 years, seizures (other than febrile seizures) in 
children younger than 2 years, and suspicion of sepsis in 
children younger than 60 days. In children with 
bacteraemia, bacterial meningitis was deﬁ ned as a 
white-cell count in cerebrospinal ﬂ uid of greater than 
50x10⁶/L or a ratio of cerebrospinal ﬂ uid to plasma glucose 
less than 0·1.25,26 Serotyping of S pneumoniae was done by 
use of the Quellung reaction (Statens Seruminstitut, 
Copenhagan, Denmark) and H inﬂ uenzae by latex 
agglutination with polyclonal rabbit antiserum (Difco 
Laboratories, Detroit, MI, USA). DNA was extracted 
retrospectively from the frozen samples collected at 
admission by use of Qiagen DNA blood mini kits (Qiagen, 
Crawley, UK) and typed for sickle-cell anaemia by PCR.21 
Statistical analysis 
We compared the means of normally distributed 
continuous data by use of Student’s t tests and medians 
of non-normally distributed data by the Kruskal-Wallis 
test. We calculated odds ratios (ORs) for sickle-cell 
anaemia in children with bacteraemia and each control 
group separately by both univariate and multivariable 
logistic regression analysis, with adjustment for sex, 
ethno-linguistic group, and, when possible, for division 
of residence or age in three strata. All analyses were 
done with STATA (version 10.1). We calculated the 
incidence of bacteraemia in children with sickle-cell 
anaemia from the midstudy population of the Kiliﬁ 
Epi-DSS area and the age-speciﬁ c prevalence of this 
disease in control group 1.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
During the study period, blood cultures were collected 
from 38 441 children younger than 14 years who were 
admitted to KDH from the study area. Important bacterial 
pathogens18 were cultured from 2157 (6%) cases in this 
analysis. Blood samples from 1999 (93%) children with 
bacteraemia were available for genotyping, which was 
successful in 1749 (87%). Of these children, 108 (6%) 
were homozygous for HbS, which was the only form of 
sickle-cell anaemia identiﬁ ed during this study. We noted 
no signiﬁ cant diﬀ erences between patients with 
bacteraemia who did or did not have genotyping results 
in age, prevalence of severe anaemia (haemo glo-
bin <50 g/L), or pattern of organisms isolated. However, 
because children who died at presentation were not 
investigated, typing was less complete in children who 
died in hospital (409/551, 74%) than in survivors 
(1340/1608, 83%; p<0·0001). The mass of blood cultured 
from children with bacteraemia with or without sickle-cell 
anaemia did not diﬀ er signiﬁ cantly (1·12 g vs 1·07 g; 
p=0·56). In 80 of 108 (74%) children with sickle-cell 
anaemia, the diagnosis had not previously been made at 
the time of admission.  
Table 1 summarises the organisms isolated from 
patients with bacteraemia in the groups with and without 
sickle-cell anaemia. The proportion with sickle-cell 
anaemia varied signiﬁ cantly between patients infected 
with diﬀ erent pathogens (p=0·001), and was highest for 
those infected with H inﬂ uenzae type b, non-typhi 
Salmonella species, and S pneumoniae (table 1). Five 
All (age-adjusted) 0–11 months 12–23 months ≥24 months
Overall
Any organism 26·3 (14·5–47·6) 3·9 (1·8–8·6) 24·0 (3·2–177·7) 82·0 (29·5–228·0)
Gram positive
Streptococcus pneumoniae 33·0 (17·4–62·8) 6·9 (2·7–18) 44·0 (5·7–341·4) 91·4 (30·9–269·8)
Staphylococcus aureus 6·3 (2·3–17·4) 6·7 (2·1–21) 11·7 (0·7–193·1) 0
Group B streptococci 2·9 (0·4–24·0) 2·9 (0·4–24) 0 0
Other gram-positive 
organisms*
8·8 (2·5–30·6) 1·7 (0·2–14) 0 196·7 (40·3–961·3)
Any gram-positive organism 22·9 (12·1–43·1) 4·7 (2·0–11) 28·7 (3·7–220·6) 68·3 (23·5–198·9)
Gram negative
Non-typhi Salmonella species 35·5 (16·4–76·8) 3·5 (0·9–13) 16·2 (1·7–158·9) 213·2 (67·4–674·0)
Haemophilus inﬂ uenzae type b 28·1 (12·0–65·9) 11·4 (3·8–34) 66·1 (7·0–624·3) 86·1 (18·5–400·3)
Haemophilus inﬂ uenzae other 14·8 (3·0–72·2) 0 140·5 (6·3–3122·5) 83·5 (8·6–807·8)
Escherichia coli 8·6 (3·1–23·4) 5·2 (1·5–18) 17·0 (1·5–192·9) 30·6 (3·3–282·0)
Acinetobacter species 12·6 (4·6–34·1) 3·3 (0·7–16) 0 97·7 (25·4–375·3)
Klebsiella species 2·4 (0·3–19·6) 0 46·8 (2·6–840·5) 0
Other gram-negative 
organisms†
7·5 (2·2–25·4) 0 21·6 (1·3–365·2) 81·0 (17·5–375·9)
Any gram-negative organism 25·9 (13·6–49·3) 3·3 (0·7–16) 20·1 (2·6–155·7) 99·5 (34·3–287·3)
Data are odds ratio (95% CI). Cases were 1749 children with bacteraemia, controls were 4741 children (control group 1) 
from the Kiliﬁ  Epi-DSS study area. Adjustments for sex and ethnic group made no signiﬁ cant diﬀ erence to the analysis 
(data not shown). Similarly, in a separate analysis with control group 2, we noted no signiﬁ cant eﬀ ect of division of 
residence on the odds ratios reported (data not shown). *For children without sickle-cell anaemia, species included 
streptococci groups C (n=5), D (62), F (3), and G (6); and Staphylococcus saprophyticcus (3). For children with sickle-cell 
anaemia, species included group D streptococci (2) and non-typable streptococci (2). †For children without sickle-cell 
anaemia, species included Campylobacter species (7), Enterobacter species (26), Neisseria species (10), Proteus species (10), 
Salmonella typhi (8), and Shigella species (4). For children with sickle-cell anaemia, species included Citrobacter species (1), 
Enterobacter species (2), and S typhi (1).
Table 2: Odds ratios for sickle-cell anaemia in children with bacteraemia versus controls
 For more on the UK National 
External Quality Assessment 
Service see http://www.ukneqas.
org.uk
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organisms accounted for almost 90% of isolates from 
children with sickle-cell anaemia, with the highest 
ranked being S pneumoniae, non-typhi Salmonella 
species, H inﬂ uenzae type b, Acinetobacter species, and 
E coli (table 1). A similar range of organisms was cultured 
from children with and without a previous diagnosis of 
sickle-cell anaemia. In the subset of 28 patients who 
were known to have the disease before admission, 
S pneumoniae was isolated from ten (36%), non-typhi 
Salmonella species from seven (25%), and H inﬂ uenzae 
type b from three (11%). 
Samples were available for 13 558 control children, of 
whom 13 492 (99·5%) were typed successfully. The 
proportion of children with sickle-cell anaemia in control 
group 1 was 0·3% (13/4741); it was 1·0% (eight of 782) in 
children aged 0–11 months, 0·4% (one in 282) in those 
aged 12–23 months, and 0·1% (four of 3677) in those 
aged 2–13 years. The proportion in control group 2 was 
0·9% (76/8751). 
The age-adjusted OR for sickle-cell anaemia in patients 
with bacteraemia calculated with control group 1 was 
26·3 (95% CI 14·5–47·6, p<0·0001; table 2). The strongest 
associations were for S pneumoniae, non-typhi Salmonella 
species, H inﬂ uenzae (particularly type b), Acinetobacter 
species, and E coli (table 2). Adjustments for sex, division 
of residence, and ethnic origin (and for division of 
residence with control group 2) made no signiﬁ cant 
diﬀ erence to the analysis (data not shown).  
Table 3 shows the incidence estimates for admission to 
hospital with bacteraemia in children with sickle-cell 
anaemia living within the Kiliﬁ  Epi-DSS area, both overall 
and for each of the three most common pathogens. By 
contrast with children without sickle-cell anaemia, the 
incidence of bacteraemia in children with this disease 
was higher after infancy (table 3).  
In patients with pneumococcal bacteraemia, we noted 
no signiﬁ cant diﬀ erence in distribution of serotypes 
between children with or without sickle-cell anaemia 
(table 4). 20 of 44 isolates (45%) from patients with 
sickle-cell anaemia and 146 of 425 isolates (34%) from 
patients without this disease were of serotypes 
represented in the seven-valent pneumococcal conjugate 
vaccine (p=0·17). The serotypes in the ten-valent 
pneumococcal conjugate vaccine covered 75% of 
pneumococcal isolates in patients with and without 
sickle-cell anaemia (table 4).  
To examine the eﬀ ect of H inﬂ uenzae type b conjugate 
vaccine on the association between sickle-cell anaemia 
and H inﬂ uenzae type b bacteraemia, we arbitrarily 
divided the study into three time strata representing the 
periods before (before Nov 1, 2001), during (Nov 1, 2001, 
to Oct 31, 2002), and after (after Oct 31, 2002) the 
introduction of H inﬂ uenzae type b vaccine into the 
immunisation schedule. The number of cases of 
H inﬂ uenzae type b bacteraemia detected during these 
periods was 88 before, 21 during, and 37 after the 
introduction; the proportion of sickle-cell anaemia in 
these cases was stable at 12%, 12%, and 10%, respectively 
(χ²=3·2; p=0·5).
Meningitis was diagnosed in 20 of 108 (19%) patients 
with bacteraemia who had sickle-cell anaemia, and in 
212 of 1641 (13%) without sickle-cell anaemia (p=0·1). Of 
these children with sickle-cell anaemia, S pneumoniae was 
isolated from 11, H inﬂ uenzae type b from eight, and E coli 
from one. Isolates from blood and cerebrospinal ﬂ uid 
were concordant in all cases of meningitis in which an 
organism was isolated from cerebrospinal ﬂ uid. 
Osteomyelitis was diagnosed in four patients with 
bacteraemia with sickle-cell anaemia, with non-typhi 
Salmonella species and Acinetobacter species each being 
cultured twice. In children with bacteraemia who were 
anaemic, the proportion who had sickle-cell anaemia was 
17% (30/175) compared with 5% (78/1574) in those without 
anaemia (p<0·0001). Similarly, anaemia was strongly 
associated with sickle-cell anaemia in patients with 
Events Person-years of 
observation
Incidence (95% CI)
Children without sickle-cell anaemia
All-cause bacteraemia
0–11 months 787 80 622 0·98 (0·91–1·05)
12–23 months 305 78 113 0·39 (0·35–0·44)
2–13 years 549 836 221 0·07 (0·06–0·07)
0–13 years 1641 994 956 0·17 (0·16–0·17)
Children with sickle-cell anaemia
All-cause bacteraemia
0–11 months 32 833 3·84 (2·63–5·42)
12–23 months 27 278 9·71 (6·40–14·13)
2–13 years 49 911 5·38 (3·97–7·11)
0–13 years 108 2022 5·34 (4·38–6·44)
Streptococcus pneumoniae
0–11 months 10 833 1·20 (0·58–2·20)
12–23 months 14 278 5·04 (2·75–8·45)
2–13 years 20 911 2·20 (1·34–3·39)
0–13 years 44 2022 2·18 (1·58–2·92)
Non-typhi Salmonella species
0–11 months 3 833 0·36 (0·07–1·05)
12–23 months 3 278 1·08 (0·22–3·15)
2–13 years 13 911 1·43 (0·76–2·44)
0–13 years 32 2022 1·58 (1·08–2·23)
Haemophilus inﬂ uenzae type b
0–11 months 6 833 0·72 (0·26–1·57)
12–23 months 4 278 1·44 (0·39–3·68)
2–13 years 3 911 0·33 (0·07–0·96)
0–13 years 13 2022 0·64 (0·34–1·10)
The midstudy population was 8427 for children aged 0–11 months, 8110 for those 
aged 12–23 months, and 86 006 for those aged 2–13 years; the proportions with 
sickle-cell anaemia in these age groups were 1·02% (95% CI 0·44–2·01), 0·36% 
(0·35–1·96), 0·11% (0·03–0·28), respectively. In each age group, the number of 
person-years of observation is given by the product of the midstudy population, 
the prevalence of sickle-cell anaemia, and the duration of the study in years.
Table 3: Incidence of admission to hospital with bacteraemia per 
100 person-years of observation, stratiﬁ ed by age group
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bacteraemia (OR 23·6, 95% CI 14·4–37·3). Inpatient 
mortality did not diﬀ er signiﬁ cantly between patients with 
bacteraemia with (25/108, 23%) or without (384/1641, 
23%) sickle-cell anaemia.
Discussion 
Findings from our study conﬁ rm that, as in developed 
countries, African patients with sickle-cell anaemia are at 
high risk of invasive bacterial infections, especially those 
caused by S pneumoniae, H inﬂ uenzae, and non-typhi 
Salmonella species. Furthermore, the incidence of 
pneumococcal bacteraemia in children with sickle-cell 
anaemia was similar to the range of 1·5–11·6 reported 
from developed countries before the introduction of 
antibiotic prophylaxis or pneumococcal vaccines.2,3,5,27–29 
Overall, more than 10% of episodes of pneumococcal 
bacteraemia in our study occurred in children with 
sickle-cell anaemia, three-quarters of which were of 
serotypes that are represented in the licensed ten-valent 
pneumococcal conjugate vaccine. Although the 
introduction of pneumococcal con jugate vaccine into 
routine immuni sation schedules in Africa will be of 
beneﬁ t to all, it is likely to be particularly beneﬁ cial for 
children with sickle-cell anaemia.
Studies in the USA have shown that children with 
sickle-cell anaemia are highly susceptible to bacterial 
infections, of which S pneumoniae, H inﬂ uenzae, and 
non-typhi Salmonella species are the most important.1–4 
Few studies have described the bacteriology of sickle-cell 
anaemia in sub-Saharan Africa despite the fact that more 
than 200 000 African children are born with this disease 
every year. S pneumoniae was the most common isolate 
in an early study undertaken in the Congo,13 but infections 
with S aureus, E coli, Klebsiella species, and non-typhi 
Salmonella species have predominated in recent studies 
from Uganda and Nigeria.8–12 In these studies, both 
S pneumoniae and H inﬂ uenzae were detected in-
frequently,8–12 an observation that has challenged the 
potential beneﬁ ts of antimicrobial prophylaxis in African 
patients with sickle-cell anaemia.10,12,14 However, two 
factors might account for this discrepancy. First, most 
studies have examined patients with an existing diagnosis 
of sickle-cell anaemia in a region in which infections 
with H inﬂ uenzae type b and pneumococcus occur 
predominantly in young children but most patients die 
before a diagnosis of sickle-cell anaemia is made.30 
Second, S aureus and E coli are easier to culture than are 
fastidious organisms such as pneumococcus and 
H inﬂ uenzae type b, and in laboratories with few 
resources, this diﬀ erential culture sensitivity might bias 
the distribution of the pathogens detected.
In this study, we took as our starting point children with 
bacteraemia who were detected through the surveillance 
of all children admitted to a general paediatric facility. 
This approach is unbiased by preconceptions about the 
disease status of admitted children, since our sampling 
frame included all children irrespective of their age or 
diagnosis. Moreover, the retrospective design means that 
in most cases the natural history of sickle-cell anaemia 
was unaﬀ ected by previous detection of HbSS and 
long-term medical management. Finally, we investigated 
bacteraemia in an established laboratory, meeting 
international quality assessment standards.
Our ﬁ ndings lend support to previous reports showing 
that African patients with sickle-cell anaemia are especially 
susceptible to bacteraemia caused by H inﬂ uenzae type 
b.13 Vaccination against H inﬂ uenzae type b has reduced 
the incidence of bacteraemia caused by this pathogen in 
Kiliﬁ  by 88%,20 and the consistent prevalence of sickle-cell 
anaemia in patients with H inﬂ uenzae type b before, 
during, and after introduction of the vaccination 
programme suggests that the vaccine is equally eﬀ ective 
in patients with and without this disease. This ﬁ nding 
accords with previous studies showing a brisk 
immunological response to conjugate H inﬂ uenzae type b 
vaccines in children with sickle-cell anaemia.31,32 As with 
pneumococcal conjugate vaccine, therefore, maintenance 
of the vaccine for H inﬂ uenzae type b in Kenya will be 
especially useful to children with this disease.
Although children with sickle-cell anaemia are known 
to be at increased risk of infections caused by non-typhi 
Salmonella species,33 most reports are of osteomyelitis.34,35 
In one study from Kingston, Jamaica, investigators noted 
no obvious bone involvement in half of all infections 
Isolates from children 
without sickle-cell 
anaemia
Isolates from 
children with 
sickle-cell anaemia
Total (%)
1* 127 (30·6%) 10 (22·7%) 137 (29·8%)
4† 16 (3·9%) 3 (6·8%) 19 (4·1%)
5* 37 (8·9%) 3 (6·8%) 40 (8·7%)
6A 30 (7·2%) 5 (11·4%) 35 (7·6%)
6B† 35 (8·4%) 5 (11·4%) 40 (8·7%)
7F* 1 (0·2%) 0 1 (0·2%)
13 5 (1·2%) 1 (2·3%) 6 (1·3%)
14† 38 (9·2%) 6 (13·6%) 44 (9·6%)
18C† 9 (2·2%) 2 (4·6%) 11 (2·4%)
18F 2 (0·5%) 1 (2·3%) 3 (0·7%)
19A 14 (4·0%) 3 (6·8%) 17 (3·7%)
19F† 20 (4·8%) 2 (4·6%) 22 (4·8%)
23B 0 1 (2·3%) 1 (0·2%)
23F† 28 (6·8%) 2 (4·6%) 30 (6·5%)
Others‡ 53 (13·4%) 0 53 (11·5%)
Total 415 (100%) 44 (100%) 459 (100%)
Data are the number of isolates of each serotype (% of the total isolates for each 
category). We noted no signiﬁ cant diﬀ erence in the distribution of serotypes 
between sickle-cell anaemia groups either overall (χ²=24·0, p=0·92) or for any 
serotype individually. *Additional strains represented in the ten-valent 
pneumococcal vaccine. †Strains represented in the seven-valent pneumococcal 
vaccine. We noted no occurrences of serotype 9V in either the cases with or 
without sickle-cell anaemia. ‡Included serotypes 2, 3, 7C, 8, 9A, 9L, 9V, 10A, 10B, 
11A, 12F, 15A, 15B, 15C, 16F, 18B, 19C, 21, 22A, 23A, 29, 35A, and 35B.
Table 4: Serotypes of Streptococcus pneumoniae isolates by status of 
sickle-cell anaemia
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reported.36 In our study, a diagnosis of osteomyelitis was 
recorded in only two of 19 patients with sickle-cell anaemia 
who presented with non-typhi Salmonella bacteraemia. 
Whether some of these patients had osteomylelitis that 
was poorly documented or whether this ﬁ nding indicates 
a diﬀ erence in the balance between focal and disseminated 
non-typhi Salmonella infections in patients with sickle-cell 
anaemia in our population is unclear. 
Our study suggests that the yearly incidence of 
admission to KDH with bacteraemia is 4–10 per 
100 person-years observed in young children with 
sickle-cell anaemia. These estimates are probably rather 
conservative for several reasons. First, we were 
unsuccessful in genotyping a proportion of children with 
bacteraemia for sickle-cell anaemia, and any cases missed 
as a consequence would increase these estimates. Second, 
culture of blood is an insensitive measure of the burden 
of invasive bacterial disease, especially in Kenya where 
antibiotics are available without prescription, and the true 
incidence is likely to be much higher than our estimates. 
Finally, a quarter of the children with sickle-cell anaemia 
admitted with bacteraemia died in hospital, yet we know 
that only a third of children dying in the Kiliﬁ  Epi-DSS 
area present to hospital in their ﬁ nal illness.18 Taken 
collectively, these observations suggest that invasive 
bacterial disease makes a very substantial contribution to 
the huge mortality associated with sickle-cell anaemia in 
African children. Furthermore, as developing countries 
strive to meet the Millennium Development Goals and 
reduce mortality in children younger than 5 years, the 
relative contribution of sickle-cell anaemia to childhood 
deaths will increase unless speciﬁ c interventions are 
developed to target the disease.
Our ﬁ ndings have shown that invasive bacterial 
infections make a large contribution to the morbidity and 
mortality of children with sickle-cell anaemia in Kenya. 
The dominance of just a few bacterial pathogens suggests 
that the health status and survival of children with this 
disease in Africa could be improved substantially by 
neonatal screening for aﬀ ected children or by the 
accelerated introduction into immunisation programmes 
of H inﬂ uenzae type b and pneumococcal vaccines. How 
best to identify children with sickle-cell anaemia and 
prevent bacterial infections in them should be a priority 
target for health research in Africa.
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